drugset / Trial / NCT02101333

Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

NCT02101333 ↗

NaSingle-groupOpen-labelTreatment

Summary

First-line tocilizumab treatment during 6 months could permit rapid steroid-tapering and induction of remission in Takayasu arteritis (TA).

Timeline

Start
2014-06-10
Primary completion
2018-12-10
Completion
2019-02-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous

Indications